Experts Examine Tipifarnib to Treat HNSCC With HRAS Mutations

Tipifarnib, a farnesyltransferase inhibitor, was developed 20 years ago but has yet to flnd the right patient population who derive a strong beneflt, said Perez, a head and neck medical oncologist and director of drug development at Sarah Cannon Research Institute at Florida Cancer Specialists. &quo...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncology (Williston Park, N.Y.) N.Y.), 2021-11, Vol.35 (11), p.770
Hauptverfasser:	Villafl, Victoria M, Perez, Cesar A
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Care and treatment Drug dosages Genetic aspects Medical research Medicine, Experimental Metastasis Mutation Oncology Squamous cell carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!